Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.036
Neutral
RSI(14)
53.680
Neutral
STOCH(KDJ)(9,3,3)
27.112
Sell
ATR(14)
1.722
High Vlolatility
CCI(14)
-18.738
Neutral
Williams %R
45.499
Neutral
TRIX(12,20)
0.199
Sell
StochRSI(14)
38.745
Buy
Merck & Co Inc
MRK84.120USD
+0.910+1.09%
Close 08/29, 16:00（ET）Quotes delayed by 15 min
210.56BMarket Cap
12.08P/E TTM
TradingKey Stock Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
Peers
TradingKey Stock Score
Currency: USD Updated：2025-08-29Key Insights
The company's fundamentals are relatively healthy.Its valuation is considered fairly valued,and institutional recognition is very high.Over the past 30 days, multiple analysts have rated the company as a Buy.Despite a weak stock market performance, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analysts' Target
Based on
29
analysts
Buy
Current Rating
99.454
Target Price
+19.52%
Upside Space
Disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Merck & Co., Inc. is a research-intensive biopharmaceutical company engaged in research to deliver health solutions that advance the prevention and treatment of diseases in people and animals. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. It is also engaged in developed a novel class of small molecules that target cancer cells lacking expression of a key DNA repair protein called O6-methylguanine methyl transferase.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 17.89.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 46.40%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 46.40%.
Undervalued
The company’s latest PE is 12.93, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 2.02B shares, decreasing 0.81% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 251.75M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.03.
Financial Health
Currency: USD Updated：2025-08-29The company's current financial score is 7.72, which is higher than the Pharmaceuticals & Medical Research industry's average of 6.80. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 15.53B, representing a year-over-year decrease of 1.56%, while its net profit experienced a year-over-year decrease of 6.66%.
Score
Financials
7.91
Related Indicators
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data
Quality of Earnings
7.06
Operational Efficiency
7.69
Growth Potential
8.39
Shareholder Returns
7.55
Valuation Dimension
Currency: USD Updated：2025-08-29The company’s current valuation score is 4.80, which is higher than the Pharmaceuticals & Medical Research industry's average of 1.64. Its current P/E ratio is 12.92, which is 342.03% below the recent high of 57.11 and -40.90% above the recent low of 18.21.
Score
Valuation Dimension
P/E
P/B
P/S
P/CF
Industry Ranking 27/690
No Data
Forecast
Currency: USD Updated：2025-08-29The company’s current earnings forecast score is 7.52, which is lower than the Pharmaceuticals & Medical Research industry's average of 7.96. The average price target for Merck & Co Inc is 99.00, with a high of 141.00 and a low of 82.00.
Score
Support & Resistance
No Data
Analyst Rating
Based on
29
analysts
Buy
Current Rating
99.454
Target Price
+19.52%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
178
Total
5
Median
8
Average
Company name
Ratings
Analysts
Merck & Co Inc
MRK
29
Biogen Inc
BIIB
37
Vertex Pharmaceuticals Inc
VRTX
34
Alnylam Pharmaceuticals Inc
ALNY
34
Amgen Inc
AMGN
33
Eli Lilly and Co
LLY
29
1
2
3
...
36
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
No Data
Disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Momentum
Currency: USD Updated：2025-08-29The company’s current price momentum score is 8.85, which is higher than the Pharmaceuticals & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 88.76 and the support level at 78.45, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
84.340
Sell
MA10
84.896
Sell
MA20
83.006
Buy
MA50
82.072
Buy
MA100
80.528
Buy
MA200
87.888
Sell
Institutional Confidence
Currency: USD Updated：2025-08-29The company’s current institutional recognition score is 7.00, which is higher than the Pharmaceuticals & Medical Research industry's average of 6.02. The latest institutional shareholding proportion is 80.82%, representing a quarter-over-quarter decrease of 0.79%. The largest institutional shareholder is The Vanguard, holding a total of 251.75M shares, representing 10.08% of shares outstanding, with 1.99% increase in holdings.
Score
Institutional Shareholding
No Data
Shareholder Activity
Name
Shares Held
Chg %
BlackRock Institutional Trust Company, N.A.
State Street Global Advisors (US)
Wellington Management Company, LLP
Geode Capital Management, L.L.C.
Charles Schwab Investment Management, Inc.
Norges Bank Investment Management (NBIM)
Fidelity Management & Research Company LLC
BlackRock Asset Management Ireland Limited
1
2
Risk Assessment
Currency: USD Updated：2025-08-29The U.S. Dollar Index is currently in a neutral state, which has a minor effect on the Pharmaceuticals & Medical Research mixed industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The company’s current risk assessment score is 4.60, which is higher than the Pharmaceuticals & Medical Research industry's average of 3.51. The company's beta value is 0.38. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.38
VaR
+2.06%
240-Day Maximum Drawdown
+38.07%
240-Day Volatility
+29.87%
Return
Best Daily Return
60 days
+3.35%
120 days
+5.87%
5 years
+8.37%
Worst Daily Return
60 days
-4.44%
120 days
-5.70%
5 years
-9.86%
Sharpe Ratio
60 days
+1.55
120 days
-0.59
5 years
+0.33
Risk Assessment
Maximum Drawdown
240 days
+38.07%
3 years
+44.74%
5 years
+44.74%
Return-to-Drawdown Ratio
240 days
-0.72
3 years
-0.07
5 years
+0.04
Skewness
240 days
-0.81
3 years
-0.92
5 years
-0.68
Volatility
Realised Volatility
240 days
+29.87%
5 years
+24.42%
Standardised True Range
240 days
+2.58%
5 years
+2.25%
Downside Risk-Adjusted Return
120 days
-78.22%
240 days
-78.22%
Maximum Daily Upside Volatility
60 days
+18.25%
Maximum Daily Downside Volatility
60 days
+23.40%
Liquidity
Average Turnover Rate
60 days
+0.56%
120 days
+0.61%
5 years
--
Turnover Deviation
20 days
+2.53%
60 days
+26.66%
120 days
+37.97%
Peers
Currency: USD Updated：2025-08-29Merck & Co Inc
MRK
7.05 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
Neurocrine Biosciences Inc
NBIX
7.64 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
Zoetis Inc
ZTS
7.57 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
Stoke Therapeutics Inc
STOK
7.55 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
7.54 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
7.48 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
View more
The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.
